Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Sep;5(5):404-8.
doi: 10.1097/COH.0b013e32833d1fca.

Cofactors that may influence vaccine responses

Guy de Bruyn  1
Affiliations
Review

Cofactors that may influence vaccine responses

Guy de Bruyn. Curr Opin HIV AIDS. 2010 Sep.

Abstract

Purpose of review: This review summarizes recent developments related to cofactors that may influence response to vaccination.

Recent findings: The unexpected increased HIV acquisition among vaccinees in the Step trial with prior exposure to adenovirus type 5 (Ad5) led to several studies trying to understand whether an underlying biological risk factor may have been responsible for this observation. Demographic factors and genetic background of the human populations in HIV vaccine trials remain a source of potential variation in responses observed in vaccine trials, yet empirical data remain limited on the impact of those factors. Coinfections, particularly those that may modulate the immune response, are a further concern for HIV vaccine trialists, with recent data providing further insight into effects of coinfections on innate and adaptive immunity and vaccine responses.

Summary: Individuals and human populations display variation in response to vaccination. Key explanatory variables for this variation include host factors, such as host genetics, and environmental factors, such as prior exposure to the vaccine vector, coinfection with other pathogens, and demographic factors. This review will outline some of the recent developments investigating the role of various cofactors on vaccine responses, with a particular emphasis on studies of HIV vaccines.

PubMed Disclaimer

References

    1. Colditz GA, Brewer TF, Berkey CS, Wilson ME, Burdick E, Fineberg HV, et al. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. Jama. 1994 Mar 2;271(9):698–702. - PubMed
    1. Wilson ME, Fineberg HV, Colditz GA. Geographic latitude and the efficacy of bacillus Calmette-Guerin vaccine. Clin Infect Dis. 1995 Apr;20(4):982–91. - PubMed
    1. Levine MM, Kaper JB, Herrington D, Ketley J, Losonsky G, Tacket CO, et al. Safety, immunogenicity, and efficacy of recombinant live oral cholera vaccines, CVD 103 and CVD 103-HgR. Lancet. 1988 Aug 27;2(8609):467–70. - PubMed
    1. Tacket CO, Cohen MB, Wasserman SS, Losonsky G, Livio S, Kotloff K, et al. Randomized, double-blind, placebo-controlled, multicentered trial of the efficacy of a single dose of live oral cholera vaccine CVD 103-HgR in preventing cholera following challenge with Vibrio cholerae O1 El tor inaba three months after vaccination. Infection and immunity. 1999 Dec;67(12):6341–5. - PMC - PubMed
    1. Richie EE, Punjabi NH, Sidharta YY, Peetosutan KK, Sukandar MM, Wasserman SS, et al. Efficacy trial of single-dose live oral cholera vaccine CVD 103-HgR in North Jakarta, Indonesia, a cholera-endemic area. Vaccine. 2000 May 8;18(22):2399–410. - PubMed

Publication types